About Furiex
Furiex is a Healthcare company based in Morrisville (United States) founded in 2009, and was acquired by Actavis in April 2014. Drug development for gastroenterology disorders is conducted. Furiex offers products and services including RINVOQ and TrenibotulinumtoxinE. Its focus areas include Life Sciences, Gastroenterology, Drugs and Diversified. Its legal entity is Furiex Pharmaceuticals, Inc. Its competitors include Ironwood Pharma, Ardelyx and Alcresta; 3 of its 3 listed competitors have raised funding.
Company details
Furiex Pharmaceuticals was established in 2009 in Morrisville, United States, within the pharmaceutical sector. Focus was placed on developing eluxadoline, a mu opioid receptor agonist and delta opioid receptor antagonist, targeted at diarrhea-predominant irritable bowel syndrome. Two Phase III clinical trials were completed in 2014, meeting primary endpoints for stool consistency and abdominal pain improvements as agreed with FDA and EMA. Acquisition by Actavis occurred in 2014.
Products & Services of Furiex
Furiex offers a comprehensive portfolio of products and services, including RINVOQ and TrenibotulinumtoxinE.
Treats adults with giant cell arteritis and other inflammatory conditions.
Addresses glabellar lines with rapid onset action.
Apps and channels of Furiex
its YouTube channel AbbVie has 56 subscribers and 30 videos.
Videos from Furiex
The most watched videos on Furiex's YouTube channel, AbbVie (56 subscribers). Click a video to play it here.
More on AbbVie.
Investors in Furiex
Furiex has secured backing from 1 investor. Prominent investors backing the company include Actavis.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Manufacturer of generic products | 1956 | actavis.com | Parsippany Troy Hills, United States |
Investor details for Furiex
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Furiex
3 dated milestones of Furiex across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Furiex is founded.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Actavis.
Competitors of Furiex
Furiex has 3 listed competitors in our database, 3 of them funded. They include Ironwood Pharma, Ardelyx and Alcresta.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ironwoodpharma.com | 1998 | Cambridge, United States | $206.25M | 220 | Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | |
| ardelyx.com | 2007 | Fremont, United States | $61.1M | 37 | Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. | |
| alcresta.com | 2011 | Newton, United States | $95.89M | 52 | Enzyme-based products for gastrointestinal disorders are developed using immobilization technology. |
Detailed competitors of Furiex
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Gastroenterology
3 companies that operate in the same segment as Furiex (Gastroenterology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | 1998 | Cambridge, Massachusetts, United States | USD 206.25 M | USD 296.15 M | 253 | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | |||
Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | United States | USD 1.35 B | 411 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Furiex
Furiex was founded in 2009.
Furiex is headquartered in Morrisville, United States.
Furiex Pharmaceuticals was established in 2009 in Morrisville, United States, within the pharmaceutical sector. Focus was placed on developing eluxadoline, a mu opioid receptor agonist and delta opioid receptor antagonist, targeted at diarrhea-predominant irritable bowel syndrome. Two Phase III clinical trials were completed in 2014, meeting primary endpoints for stool consistency and abdominal pain improvements as agreed with FDA and EMA. Acquisition by Actavis occurred in 2014.
Furiex's top competitors include Ironwood Pharma, Ardelyx and Alcresta.
Furiex offers RINVOQ and TrenibotulinumtoxinE.
Furiex has 1 investor. Key investors include Actavis.
Furiex operates through Furiex Pharmaceuticals, Inc.
Yes. Furiex was acquired by Actavis in April 2014.
